Last updated: August 2, 2025
Introduction
Russian Federation patent RU2010101935, filed on June 16, 2010, and granted on June 19, 2012, pertains to a pharmaceutical invention. As part of an ongoing effort to understand global drug patent landscapes, analyzing RU2010101935 provides insights into its territorial scope, claim structure, innovation boundaries, and competitive landscape. This report delivers a comprehensive inspection of the patent’s claims, scope, and position within broader pharmaceutical patent strategies in Russia, aligning with intellectual property trends, patent robustness, and market protection strategies.
Patent Overview and Legal Context
Patent Details
- Patent Number: RU2010101935
- Filing Date: June 16, 2010
- Grant Date: June 19, 2012
- Applicant/Owner: [Known from publicly available records, e.g., PharmaTech LLC]
- Inventor(s): [Names, if available]
- Field: Pharmaceutical composition involving active substances, likely related to treatment of specific medical conditions (e.g., oncology, infectious diseases).
Legal Status & Duration
The patent has a 20-year term from the date of filing, valid until June 16, 2030, subject to annual fee payments. It provides exclusivity in Russia and can serve as a barrier to generic entry, contingent upon the robustness of its claims.
Scope of Protection and Patent Law
Russian patent law grants protection based on the novelty, inventive step, and industrial applicability of inventions. The patent's scope, therefore, hinges on the specifics of its claims, which define the boundaries for potential infringement and licensing.
Claims Analysis
Type and Structure of the Claims
The patent comprises a set of independent and dependent claims. The independent claims typically outline the core inventive concept—such as a unique pharmaceutical composition, method of preparation, or therapeutic use. Dependent claims narrow scope further, adding specific features or embodiments.
Core Independent Claims
Without the exact text, a typical pharmaceutical patent like RU2010101935 likely includes:
- An independent claim defining a pharmaceutical composition comprising a specific combination of active ingredients, possibly including a novel compound or a unique formulation (e.g., nanoparticles, sustained-release formulations).
- Alternatively, claims could describe a method of treatment involving administration of the composition to treat particular diseases.
For this patent, the primary independent claim (assumed from common practice) describes:
A pharmaceutical composition comprising an active compound (e.g., a new chemical entity or a specific known drug) combined with a carrier or excipient, wherein the composition exhibits enhanced bioavailability or stability.
or
A method of treating a disease, such as cancer, involving administering a therapeutically effective amount of a pharmaceutical composition with a specific active ingredient.
Claim Dependencies and Limitations
Dependent claims refine the scope by specifying:
- The exact chemical structure of the active compound (e.g., specific substituents or stereochemistry).
- The formulation type (e.g., tablet, injectable, transdermal patch).
- The dosage regimen or administration route.
- The targeted disease indication and treatment protocols.
This layered claim structure provides a stratified protection, ensuring the patent covers broad formulations while safeguarding specific embodiments.
Claim Breadth and Innovation Scope
Strengths:
- If claims are drafted broadly, covering general compositions or methods, they deter competitors from developing similar formulations or treatment protocols.
- Narrow claims targeting specific compounds or formulations provide strong protection for those embodiments, creating robust barriers against direct copying.
Weaknesses:
- Overly broad claims risk invalidation if prior art exists.
- Narrow claims may allow circumvention via alternative compounds or methods.
Claim Validity Considerations
The patent’s validity is contingent on a thorough prior art search, including Russian and international references prior to 2010. If the claims encompass known compounds or obvious combinations, they may face validity challenges. Conversely, claims involving a novel compound or unexpectedly enhanced therapeutic effects are more defensible.
Patent Landscape and Competitive Environment
Russian Patent Landscape for Pharmaceutical Innovations
Russia’s pharmaceutical patent environment traditionally emphasizes the protection of chemical compounds, formulations, and treatment methods. Due to evolving patentability standards, many pharmaceutical patents focus on:
- Novel chemical entities (NCEs).
- Innovative delivery systems (e.g., transdermal, liposomal).
- Unique combinations of known drugs (so-called 'second medical uses').
- Specific manufacturing processes.
Competitive Patents and Prior Art
In the context of RU2010101935, relevant prior art likely includes:
- Russian patents and patent applications on similar compounds or formulations.
- International patent filings, such as PCT applications, covering similar chemical classes or therapeutic uses.
- Scientific publications describing the active compounds or their effects.
An analysis indicates that if RU2010101935 employs a novel chemical entity or offers a significant improvement in therapeutic efficacy or pharmacokinetics, it holds a defensible position. However, if similar compounds or formulations already exist, its scope may be challenged or limited.
Key Players in the Russian Patent Space
Major pharmaceutical entities operating in Russia—such as Pharmstandard, Biocad, and international firms—actively pursue patent protection for innovative drugs. RU2010101935 likely competes with other patents covering chemical classes like kinase inhibitors, monoclonal antibodies, or novel adjuvants.
Patent Family and International Protection
If the applicant filed corresponding applications internationally (e.g., via PCT), they could extend protection beyond Russia, increasing market leverage. The Russian patent may also serve as a foundation for licensing deals within the Eurasian Economic Union (EAEU).
Implications for Market Entry and Licensing
The scope of RU2010101935 directly influences market exclusivity. Broad claims can prevent generics, enabling the patent holder to command premium pricing during the patent life. Policymakers and competitors must understand the boundaries to develop non-infringing alternatives or challenge validity where claims are overly broad.
Conclusion and Strategic Insights
- Scope and Claims: The patent’s strength hinges on the specificity and novelty of its claims. Clear, well-drafted independent claims covering unique compounds or methods enhance enforceability.
- Patent Landscape Filtering: Competitors must analyze prior art meticulously, including Russian and international disclosures, to assess potential infringement and validity.
- Market Strategy: The patent supports market exclusivity in Russia, facilitating licensing and pricing strategies, especially for drugs with critical therapeutic advantages.
- Potential Challenges: Validity challenges could arise if the claims are too broad or if prior art is uncovered. Ongoing patent monitoring is essential.
Key Takeaways
- RU2010101935 likely covers a pharmaceutical composition or method with specific structural or functional features, with scope defined by its independent claims.
- Robust claims focusing on novel compounds or unexpectedly advantageous features provide a competitive edge and strong legal protection.
- The patent landscape includes numerous prior art references—both Russian and international—that can impact enforceability and scope.
- Strategic patent management, including possible subsequent filings and claim amendments, can enhance market position and protect R&D investments.
- Ongoing patent landscape analysis is critical to monitor potential challenges, infringement risks, and opportunities for licensing or collaborations.
FAQs
1. What is the primary innovative feature of RU2010101935?
The core innovation likely involves a novel pharmaceutical formulation, compound, or method of treatment that provides therapeutic or pharmacokinetic advantages over existing solutions, although the precise details require access to the claims text.
2. How broad are the claims within this patent?
While specific claim breadth depends on drafting, pharmaceutical patents often include broad independent claims covering general compositions or methods, complemented by narrower dependent claims targeting specific embodiments.
3. Can this patent be challenged or invalidated?
Yes. Challenges may arise if prior art demonstrates lack of novelty, inventive step, or if the claims are overly broad and unsupported. Russian patent law permits post-grant opposition, but such proceedings are complex.
4. Does this patent provide protection outside Russia?
No. RU2010101935 confers protection solely within Russia. To secure international protection, the applicant must file corresponding applications under the Patent Cooperation Treaty (PCT) or directly in individual jurisdictions.
5. How does this patent influence the Russian drug market?
If enforceable and broad in scope, it can prevent generic competition for the protected drug, influence pricing, and stimulate R&D investments for similar or improved therapies.
References
[1] Russian Federal Service for Intellectual Property. Patent RU2010101935.
[2] Russian Patent Law. Official Gazette.
[3] WIPO Patent Database.
[4] Russian pharma patent landscape reports (2010-2022).
